Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In healthy subjects, the incretin effect during an oral glucose tolerance test increases with the size of glucose load, resulting in similar glucose excursions independently of the glucose loads. Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown. RESEARCH DESIGN AND METHODS: Incretin effect was measured over 6 d by means of three 4-h oral glucose tolerance test with increasing glucose loads (25, 75, and 125 g) and three corresponding isoglycemic iv glucose infusions in eight patients with T2DM [fasting plasma glucose, mean 7.7 (range 7.0-8.9) mM; glycosylated hemoglobin, 7.0% (6.2-8.4%)] and eight matched healthy control subjects [fasting plasma glucose, 5.3 (4.8-5.7) mM; glycosylated hemoglobin, 5.4% (5.0-5.7%)]. RESULTS: Patients with T2DM exhibited higher peak plasma glucose in response to increasing oral glucose loads, whereas no differences in peak plasma glucose values among control subjects were observed. The incretin effect was significantly (P < 0.003) lower in patients with T2DM (0 ± 7, 11 ± 9, and 36 ± 5%) as compared with control subjects (36 ± 5, 53 ± 6, and 65 ± 6%). Equal and progressively delayed gastric emptying due to the increasing loads was found in both groups. Incretin hormone responses were similar. CONCLUSIONS: Up-regulation of the incretin effect in response to increasing oral glucose loads seems to be crucial for controlling glucose excursions in healthy subjects. Patients with T2DM are characterized by an impaired capability to regulate their incretin effect, which may contribute to the exaggerated glucose excursions after oral ingestion of glucose in these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well-known that the incretin effect is weakened or no longer present in subjects with T2D, albeit more or less normal secretion of GIP e GLP-1 [16,17,18].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [17]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 2×
“The incretin effect is gauged by comparing insulin responses after oral ingestion of glucose and isoglycemic iv glucose infusion (IIGI), respectively (6).”
BackgroundMethodTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 6×
“(7) and us among healthy subjects are likely to result from deceleration of gastric emptying in response to the larger oral glucose loads as indicated by the acetaminophen results of the present study.”
BackgroundResultInfluentialDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Cauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationVilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528 · cited 1×
“Furthermore, reduced postprandial GLP-1 responses (20, 28), decreased insulinotropic potency of GLP-1 (29) and an almost complete loss of insulin secretion in response to GIP (21, 30) have been proposed as potential contributors to the impaired incretin effect in T2DM.”
BackgroundSelf-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 1×
“Furthermore, reduced postprandial GLP-1 responses (20, 28), decreased insulinotropic potency of GLP-1 (29) and an almost complete loss of insulin secretion in response to GIP (21, 30) have been proposed as potential contributors to the impaired incretin effect in T2DM.”
BackgroundIncretins, insulin secretion and Type 2 diabetes mellitus
Vilsbøll, T., & Holst, J. J. (2004) · Diabetologia · doi:10.1007/s00125-004-1342-6 · Cited by 444
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationHøjberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Self-citationPerley, M., & Kipnis, D. M. (1966) · Diabetes · doi:10.2337/diab.15.12.867 · Cited by 330
The analysis of repeated measures designs: A review
Keselman, H. J., Algina, J., & Kowalchuk, R. K. (2001) · British Journal of Mathematical and Statistical Psychology · doi:10.1348/000711001159357 · Cited by 306
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
Meyer, C., Stumvoll, M., Nadkarni, V, Dostou, J., Mitrakou, A., & Gerich, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2415 · Cited by 300
New developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Bablok, W., Passing, H., Bender, R., & Schneider, B. (1988) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.1988.26.11.783 · Cited by 222
Mogensen, C. E. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109090668 · Cited by 221
How Useful Is Paracetamol Absorption as a Marker of Gastric Emptying? A Systematic Literature Study
Willems, M., Quartero, A. O., & Numans, M. E. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011935603893 · Cited by 211 · cited 2×
“provides an indirect estimation of gastric emptying and some inter-individual variation) (24, 25).”
BackgroundMethodPilichiewicz, A. N., Chaikomin, R., Brennan, I. M., Wishart, J. M., Rayner, C. K., Jones, K. L., Smout, A. J. P. M., Horowitz, M., & Feinle-Bisset, C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00159.2007 · Cited by 195
Knop, F. K., Vilsbøll, T., Madsbad, S., Holst, J. J., & Krarup, T. (2007) · Diabetologia · doi:10.1007/s00125-006-0566-z · Cited by 193
Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0119 · Cited by 110
Krarup, T., & Holst, J. J. (1984) · Regulatory Peptides · doi:10.1016/0167-0115(84)90005-3 · Cited by 109
Preserved Inhibitory Potency of GLP-1 on Glucagon Secretion in Type 2 Diabetes Mellitus
Hare, K. J., Knop, F. K., Asmar, M., Madsbad, S., Deacon, C. F., Holst, J. J., & Vilsbøll, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0921 · Cited by 102
Medhus, A. W., Lofthus, C. M., Bredesen, J., & Husebye, E. (2001) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2001.00249.x · Cited by 96
Validation of methods for measurement of insulin secretion in humans in vivo.
Kjems, L. L., Christiansen, E., Vølund, A., Bergman, R. N., & Madsbad, S. (2000) · Diabetes · doi:10.2337/diabetes.49.4.580 · Cited by 80
Kjems, L., Vølund, A., & Madsbad, S. (2001) · Diabetologia · doi:10.1007/s001250100639 · Cited by 62
Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography.
Miceli, J. N., Aravind, M. K., Cohen, S. N., & Done, A. K. (1979) · Clinical Chemistry · doi:10.1093/clinchem/25.6.1002 · Cited by 50
Sanaka, M., & Nakada, K. (2008) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2008.30.10.1316828 · Cited by 7
Research works printed but not linked: 3
- Willms, 1994, Inhibition of gastric emptying by glucagon-like peptide (7-36) amide in patients with type-2 diabetes mellitus., Diabetologia, 37, A118
- Knop, 2009, Glucagon responses to increasing oral loads of glucose and corresponding isoglycemic intravenous glucose infusions in patients with type 2 diabetes and healthy subjects., Diabetes, 58, A368
- Knop, 2008, Redcuced incretin effect in obese subjects with normal glucose tolerance as compared to lean control subjects., Diabetes, 57, A410
Cited by
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“As the consequence of the dose-dependent secretion and insulinotropic action of the incretin hormones GIP and GLP-1, widely different oral glucose loads lead to an almost uniform plasma glucose concentration profile.(38,39) The explanation is the variation in the quantitative contribution of the incretin effect to the…”
BackgroundSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
“In addition, pharmacological manipulation of gastric emptying of a solid-liquid mixed-nutrient meal produced corresponding glycemic changes in patients with T2DM (285).”
BackgroundInfluentialNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Impact of postprandial glycaemia on health and prevention of disease
Blaak, E. E., Antoine, J. ‐., Benton, D., Björck, I., Bozzetto, L., Brouns, F., Diamant, M., Dye, L., Hulshof, T., Holst, J. J., et al. (2012) · Obesity Reviews · doi:10.1111/j.1467-789x.2012.01011.x · Cited by 477
Metadata
- Authors
- Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T.
- Affiliations
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
- University of Copenhagen (DK)
- Corresponding author
- Vilsbøll, Tina
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-03-01
- Volume
- 96
- Issue
- 3
- Pages
- 737-745
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2041551639
- Cited by
- 219
- References
- 33
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 14 · 2023: 15 · 2022: 8 · 2021: 14 · 2020: 15 · 2019: 18 · 2018: 11 · 2017: 14 · 2016: 25 · 2015: 17 · 2014: 14 · 2013: 23 · 2012: 10
- FWCI
- 14.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- incretin effect, type 2 diabetes, oral glucose tolerance test, glucose load, glycemic excursions, gastric emptying, glucose homeostasis
- MeSH terms
- Insulin Secretion, Acetaminophen, Adult, Aged, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 2, Female, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucose, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Analgesics, Non-Narcotic, Area Under Curve, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.